NovoCure Ltd (NVCR)
Data as of , from SEC Form 4 filings.
See up to 3 months of NVCR. The 7-day demo opens the 1M and 3M ranges and puts NVCR on your watchlist.
Start 7-day demoLatest NVCR insider trades
About NovoCure Ltd (NVCR)
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
- ST. HELIER
- 1,605
- 2015
- XNAS
NVCR Form 4 activity by transaction type, last 90 days
No Form 4 activity for NVCR in the last 90 days.
NVCR insider transactions (Form 4)
5756 Form 4 filings on record, the earliest from Nov 4, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michal Nath Puri - Officer | Grant or award | Ordinary Shares | 1,905 | $11.15 footnote F2 | $21K | |
| ||||||
| Frank X. Leonard - Officer | Grant or award | Ordinary Shares | 1,905 | $11.15 footnote F2 | $21K | |
| ||||||
| Arye Barak Ben - Officer | Grant or award | Ordinary Shares | 1,299 | $11.15 footnote F2 | $14K | |
| ||||||
 Asaf Danziger | Grant or award | Ordinary Shares | 268 | $11.15 footnote F2 | $3K | |
| ||||||
| Frank X. Leonard - Officer | Open-market sale | Ordinary Shares | 34,273 footnote F1 | $17.93 footnote F2 | $615K | |
| ||||||
| Gabriel Leung | Grant or award | Ordinary Shares | 11,610 | $0.00 | - | |
| Gabriel Leung | Grant or award | Stock Option (Right to Buy) | 16,999 | $0.00 | - | |
| Kristin Stafford | Grant or award | Ordinary Shares | 11,610 | $0.00 | - | |
| Kristin Stafford | Grant or award | Stock Option (Right to Buy) | 16,999 | $0.00 | - | |
| Allyson J. Ocean | Grant or award | Ordinary Shares | 11,610 | $0.00 | - | |
| Allyson J. Ocean | Grant or award | Stock Option (Right to Buy) | 16,999 | $0.00 | - | |
| Timothy J. Scannell | Grant or award | Ordinary Shares | 11,610 | $0.00 | - | |
| Timothy J. Scannell | Grant or award | Stock Option (Right to Buy) | 16,999 | $0.00 | - | |
| Jeryl L. Hilleman | Grant or award | Ordinary Shares | 11,610 | $0.00 | - | |
| Jeryl L. Hilleman | Grant or award | Stock Option (Right to Buy) | 16,999 | $0.00 | - | |
 David Hung | Grant or award | Ordinary Shares | 11,610 | $0.00 | - | |
| David Hung | Grant or award | Stock Option (Right to Buy) | 16,999 | $0.00 | - | |
| Martin J. Madden | Grant or award | Ordinary Shares | 11,610 | $0.00 | - | |
| Martin J. Madden | Grant or award | Stock Option (Right to Buy) | 16,999 | $0.00 | - | |
| W. Anthony Vernon | Grant or award | Ordinary Shares | 11,610 | $0.00 | - | |
| W. Anthony Vernon | Grant or award | Stock Option (Right to Buy) | 16,999 | $0.00 | - | |
| Gabriel Leung | Open-market sale | Ordinary Shares | 2,945 footnote F1 | $15.77 footnote F2 | $46K | |
| ||||||
| Kristin Stafford | Open-market sale | Ordinary Shares | 2,945 footnote F1 | $15.77 footnote F2 | $46K | |
| ||||||
| Allyson J. Ocean | Open-market sale | Ordinary Shares | 2,945 footnote F1 | $15.77 footnote F2 | $46K | |
| ||||||
| Timothy J. Scannell | Open-market sale | Ordinary Shares | 2,945 footnote F1 | $15.77 footnote F2 | $46K | |
| ||||||
| Jeryl L. Hilleman | Open-market sale | Ordinary Shares | 2,945 footnote F1 | $15.77 footnote F2 | $46K | |
| ||||||
| W. Anthony Vernon | Open-market sale | Ordinary Shares | 2,945 footnote F1 | $15.77 footnote F2 | $46K | |
| ||||||
| David Hung | Open-market sale | Ordinary Shares | 2,945 footnote F1 | $15.77 footnote F2 | $46K | |
| ||||||
| W. Anthony Vernon | Option exercise | Ordinary Shares | 21,500 | $11.39 | $245K | |
| W. Anthony Vernon | Option exercise | Stock Option (Right to Buy) | 21,500 | $0.00 | - | |
| Nicolas Leupin - Officer | Open-market sale | Ordinary Shares | 1,100 footnote F1 | $13.31 footnote F2 | $15K | |
| ||||||
| Ashley Cordova - Officer | Tax withholding / forfeiture | Ordinary Shares | 17,638 footnote F1 | $13.30 | $235K | |
| ||||||
| Arye Barak Ben - Officer | Grant or award | Ordinary Shares | 50,125 | $0.00 | - | |
| Arye Barak Ben - Officer | Grant or award | Stock Option (Right to Buy) | 73,340 | $0.00 | - | |
| Uri Weinberg - Officer | Grant or award | Ordinary Shares | 50,125 | $0.00 | - | |
| Uri Weinberg - Officer | Open-market sale | Ordinary Shares | 6,412 footnote F2 | $13.31 footnote F3 | $85K | |
| Uri Weinberg - Officer | Grant or award | Stock Option (Right to Buy) | 73,340 | $0.00 | - | |
| ||||||
 Christoph Brackmann - Officer | Grant or award | Stock Option (Right to Buy) | 80,674 | $0.00 | - | |
| Christoph Brackmann - Officer | Grant or award | Ordinary Shares | 55,137 | $0.00 | - | |
| Christoph Brackmann - Officer | Open-market sale | Ordinary Shares | 6,412 footnote F2 | $13.31 footnote F3 | $85K | |
| ||||||
| Frank X. Leonard - Officer | Grant or award | Ordinary Shares | 150,000 | $0.00 | - | |
| Frank X. Leonard - Officer | Open-market sale | Ordinary Shares | 5,607 footnote F2 | $13.31 footnote F3 | $75K | |
| Frank X. Leonard - Officer | Grant or award | Stock Option (Right to Buy) | 216,388 | $0.00 | - | |
| ||||||
| Mukund Paravasthu - Officer | Open-market sale | Ordinary Shares | 5,377 footnote F2 | $13.31 footnote F3 | $72K | |
| Mukund Paravasthu - Officer | Open-market sale | Ordinary Shares | 43,246 | $13.77 footnote F4 | $596K | |
| Mukund Paravasthu - Officer | Grant or award | Stock Option (Right to Buy) | 7,518 | $0.00 | - | |
| Mukund Paravasthu - Officer | Grant or award | Stock Option (Right to Buy) | 58,488 | $0.00 | - | |
| Mukund Paravasthu - Officer | Grant or award | Ordinary Shares | 45,112 | $0.00 | - | |
| ||||||
| Michal Nath Puri - Officer | Grant or award | Ordinary Shares | 40,100 | $0.00 | - | |
| Michal Nath Puri - Officer | Open-market sale | Ordinary Shares | 1,100 footnote F2 | $13.31 footnote F3 | $15K | |
| Michal Nath Puri - Officer | Grant or award | Stock Option (Right to Buy) | 58,672 | $0.00 | - | |
| ||||||
| William F. Doyle - Officer | Grant or award | Ordinary Shares | 200,000 | $0.00 | - | |
| William F. Doyle - Officer | Grant or award | Ordinary Shares | 200,284 | $0.00 | - | |
| William F. Doyle - Officer | Open-market sale | Ordinary Shares | 50,557 footnote F3 | $12.79 footnote F4 | $646K | |
| William F. Doyle - Officer | Open-market sale | Ordinary Shares | 21,330 footnote F3 | $13.43 footnote F5 | $286K | |
| William F. Doyle - Officer | Grant or award | Stock Option (Right to Buy) | 258,445 | $0.00 | - | |
| William F. Doyle - Officer | Grant or award | Stock Option (Right to Buy) | 30,072 | $0.00 | - | |
| ||||||
Item 7.01, 9.01
Item 5.02, 9.01
Item 8.01, 9.01
Item 2.02, 9.01
Recent NVCR Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
NVCR insider trading FAQ
What is the latest insider trade for NVCR?
NovoCure Ltd (NVCR) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-01. The full record for NVCR runs to 56 Form 4 filings, the earliest from 2024-11-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying NVCR stock?
No insider purchases of NVCR were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling NVCR stock?
No insider sales of NVCR were filed in the last 90 days. 31 sales are on record for this company.
Where can I see NVCR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects NVCR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michal Nath Puri view on EDGAR
- - Frank X. Leonard view on EDGAR
- - Arye Barak Ben view on EDGAR
- - Asaf Danziger view on EDGAR
- - Frank X. Leonard view on EDGAR
- - Gabriel Leung view on EDGAR
- - Kristin Stafford view on EDGAR
- - Allyson J. Ocean view on EDGAR
- - Timothy J. Scannell view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where NVCR's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow NVCR with a 7-day demo
- NVCR on your watchlist
- Every NVCR Form 4 filing on record
- Up to 3 months of NVCR price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
